摘要
目的探讨康士德(比卡鲁胺)联合诺雷德(戈舍瑞林)对中晚期前列腺癌患者术后的疗效及对患者血清前列腺特异性抗原和α-甲酰基辅酶A消旋酶的影响。方法 63例中晚期前列腺癌患者随机分为两组,行经尿道前列腺等离子双极电切术联合手术去势后,对照组患者术后给予诺雷得植入剂治疗,观察组患者术后在对照组的基础上加服康士德治疗,观察治疗前后血清前列腺特异性抗原及α-甲酰基辅酶A消旋酶的变化。结果两组患者血清中前列腺特异性抗原和α-甲酰基辅酶A消旋酶的含量均较治疗前下降>70%(P<0.01),其中观察组血清中前列腺特异性抗原和α-甲酰基辅酶A消旋酶值较对照组下降更为明显(P<0.01,P<0.05)。结论康士德联合诺雷德对中晚期前列腺癌患者术后安全、有效,可明显降低患者血清前列腺特异性抗原和α-甲酰基辅酶A消旋酶的含量。
Objective To investigate the safety and feasibility of Cascodex( Biealutamide) combined with Zoladex in metaphase- advanced prostate cancer,and the effect on PSA and P540 S. Methods 63 patients with Metaphase- advanced prostate cancer were randomly divided into two groups. The control group was treated with Zoladex,and the observation group was applied with Cascodex and Zoladex after TUPKP and surgical castration. The patient's PSA and P540 S in serum were observed. The safety and adverse drug reaction of the method was also evaluated. Results After treatment the PSA and P540 S in serum were improved in the both group,showing statistical difference when compared with before treatment( P< 0. 01),and the Inhibit rate of decline in serum PSA and P540 S levels in observation group was significantly higher than the control group( P < 0. 01,P < 0. 05). Conclusion Cascodex combined with Zoladex in metaphase- advanced prostate cancer was effective and it can decline the PSA and P540 S in serum significantly.
出处
《药学研究》
CAS
2015年第9期544-546,共3页
Journal of Pharmaceutical Research
基金
广东省科技攻关项目(No.2011B031800228)
